Literature DB >> 23454515

Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines.

Guillaume Burgy1, Tania Tahtouh, Emilie Durieu, Béatrice Foll-Josselin, Emmanuelle Limanton, Laurent Meijer, François Carreaux, Jean-Pierre Bazureau.   

Abstract

Leucettines, a family of marine sponge-derived 2-aminoimidazolone alkaloids, are potent inhibitors of DYRKs (dual-specificity, tyrosine phosphorylation regulated kinases) and CLKs (cdc2-like kinases). They constitute promising pharmacological leads for the treatment of several diseases, including Alzheimer's disease and Down syndrome. In order to investigate the scope of potential targets of Leucettine L41, a representative member of the chemical class, we designed an affinity chromatography strategy based on agarose-immobilized leucettines. A synthesis protocol for the attachment of a polyethylene (3 or 4 units) linker to L41 was first established. The linker attachment site on L41 was selected on the basis of the co-crystal structure of L41 with several kinases. L41 was then covalently bound to agarose beads through the primary amine located at the end of the linker. Control, kinase inactive Leucettine was also immobilized, as well as free linker devoid of ligand. Extracts of several mouse tissues revealed a complex pattern of interacting proteins, some of which probably resulting from non-specific, hydrophobic binding, while others representing bona fide Leucettine-interacting proteins. DYRK1A and GSK-3 (glycogen synthase kinase-3) were confirmed as interacting targets by Western blotting in various mouse tissues. The Leucettine affinity chromatography resin constitutes a powerful tool to purify and identify the targets of this new promising therapeutic class of molecules.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23454515     DOI: 10.1016/j.ejmech.2013.01.035

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  New 5-ylidene rhodanine derivatives based on the dispacamide A model.

Authors:  Solene Guiheneuf; Ludovic Paquin; François Carreaux; Emilie Durieu; Thierry Roisnel; Laurent Meijer; Jean-Pierre Bazureau
Journal:  Mol Divers       Date:  2014-03-02       Impact factor: 2.943

Review 2.  Marine Pharmacology in 2012-2013: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action.

Authors:  Alejandro M S Mayer; Abimael D Rodríguez; Orazio Taglialatela-Scafati; Nobuhiro Fusetani
Journal:  Mar Drugs       Date:  2017-08-29       Impact factor: 5.118

3.  [b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors.

Authors:  Christian Lechner; Maren Flaßhoff; Hannes Falke; Lutz Preu; Nadége Loaëc; Laurent Meijer; Stefan Knapp; Apirat Chaikuad; Conrad Kunick
Journal:  Molecules       Date:  2019-11-13       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.